Currently playing a critical role in delivering hope for a post-pandemic future, Pfizer is making cell and gene therapies important components in its drug development portfolio. This conversation will explore the development of the Pfizer/BioNTech COVID-19 vaccine and scientific opportunity for mRNA, Pfizer’s efforts in gene therapy for some rare diseases, the role of partnerships and collaborations in the Pfizer strategy, and how the company plans to address manufacturing and bioprocessing needs as CGT products emerge.